Accredited for 1.0 AMA PRA Category 1 Credits™
Medication Assisted Treatment for Opioid Use Disorders
Emily Zarse, MD
Area Chief of Addiction Psychiatry
Eskenazi Health Midtown Community Mental Health Center
About the speaker:
Emily Zarse, MD, is an addiction psychiatrist who practices in a dual-diagnosis clinic, treating patients with co-occurring mental illness and substance use disorders. Dr. Zarse co-leads the Opioid Learning Collaborative, which works to improve access to treatment for opioid-dependent patients in primary care as well as to improve provider knowledge on substance use disorders and the use of medication-assisted treatment (MAT). She is a buprenorphine waiver trainer through the American Academy of Addiction Psychiatry and the American Psychiatric Association. Dr. Zarse also collaborates with Eskenazi Health’s emergency department on Project POINT, which aims to improve access to treatment for opiate-overdose patients.
Addiction to opioids has reached epidemic proportions in the United States, and communities across the country face increased demands for prevention and substance use services.
Behavioral health organizations increasingly use evidence-based practices such as medication assisted treatment (MAT) to combat the crisis. This “whole patient” approach to the treatment of substance use disorders has been found to substantially improve the odds of successful recovery for people who misuse opioids, including heroin and prescription painkillers.
Because of the way opioids affect the brain, behavioral treatments such as therapy and 12-step programs are found to be more effective when used in combination with medication. Research has shown that this approach can be very effective in helping opioid users stay in recovery for years or even decades.
At the end of this webinar, attendees will be able to:
- Understand MAT’s use of medication in combination with counseling and behavioral therapy.
- Outline the benefits of MAT.
- Describe the three primary medications used to treat opioid dependence and addiction.
- Understand the neurobiology of addiction and how MAT works on neurobiological changes.
- Identify appropriate duration of treatment.
- Recognize MAT misconceptions – myths vs. facts.
- Cite MAT treatment centers in Indiana.
Designation Statement: The Indiana State Medical Association (ISMA) designates this live webinar for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation Statement: The Indiana State Medical Association (ISMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Note: While offering the CME credit hours listed in these pages, these activities are not intended to provide extensive training in a field.
Disclosure: In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by the ISMA must demonstrate balance, independence, objectivity and scientific rigor. Prior to the activity, all faculty, authors, editors and planning committee members participating in an ISMA-sponsored activity are required to disclose to attendees any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Supported by an Educational Grant from:
If you have questions, you may contact ISMA – Continuing Medical Education staff at (800) 257-4762 or by email at firstname.lastname@example.org.
REGISTRATION DEADLINE: October 18 @ 11:00 AM